• Biodegradable IR-1061 Nanoparticles for Deep NIR-II In Vivo

  2026-06-19

  The reference study introduces a one-pot method to encapsulate the near infrared fluorescent dye IR-1061 within biodegradable PEG-b-PCL micellar nanoparticles, addressing the challenges of deep tissue imaging in the NIR-II window. This approach streamlines nanoparticle preparation and enhances biocompatibility, with significant implications for advanced molecular imaging in biomedical research.

• Tunneling Nanotubes Enable KRas Transfer and Alter Tumor Mec

  2026-06-19

  This study demonstrates that tunneling nanotubes (TNTs) mediate the intercellular transfer of mutant KRas, reducing membrane tension and increasing phospholipid flow in tumor cells. These mechanical changes enhance tumor heterogeneity and metastatic potential, suggesting new markers and therapeutic targets for malignancy.

• Chloroquine (SKU BA1002): Reliable Research Solutions in Cel

  2026-06-18

  This article delivers an evidence-based, scenario-driven guide to optimizing cell viability, proliferation, and cytotoxicity assays using Chloroquine (SKU BA1002). Researchers will find practical insights on protocol design, data interpretation, and vendor selection, with a focus on reproducibility and validated performance. APExBIO’s Chloroquine is highlighted as a dependable choice for biomedical workflows.

• Naftifine HCl in Antifungal Research: Workflows & Optimizati

  2026-06-18

  Naftifine HCl, a high-purity allylamine antifungal agent from APExBIO, is redefining experimental protocols for dermatophyte research by enabling precise inhibition of fungal membrane biosynthesis. This article delivers stepwise workflows, advanced troubleshooting strategies, and unique insights drawn from pioneering cell signaling studies to help researchers maximize reproducibility and data quality in antifungal assays.

• JNK-IN-7: Selective JNK Inhibitor Optimizes Apoptosis Assays

  2026-06-17

  JNK-IN-7 empowers researchers to precisely dissect JNK-dependent apoptosis and Toll receptor signaling in cell-based models. This article translates cutting-edge findings and protocol strategies into actionable workflows, troubleshooting, and performance enhancements for MAPK pathway research.

• MG-132 (Z-LLL-al): Precision Proteasome Inhibition in Apopto

  2026-06-17

  MG-132 (Z-LLL-al) empowers researchers to dissect proteasome-dependent apoptosis, cell cycle arrest, and oxidative stress with unmatched selectivity and workflow flexibility. Leverage APExBIO’s trusted reagent to optimize cancer and ferroptosis resistance studies with robust, reproducible outcomes.

• Maraviroc (UK-427857): Precision CCR5 Antagonist for HIV and

  2026-06-16

  Maraviroc (UK-427857) from APExBIO stands out as a selective CCR5 antagonist, enabling robust HIV-1 entry inhibition and innovative neuroinflammation research. This guide translates complex mechanisms into actionable workflows, with practical troubleshooting and protocol enhancements tailored for infection and ischemic stroke models.

• U0126 (SKU BA2003): Reliable MEK1/2 Inhibition in Cell Assay

  2026-06-16

  U0126 (SKU BA2003) is a benchmark MEK1/2 inhibitor for precise modulation of MAPK/ERK signaling, crucial for cell viability and cytotoxicity assays. This article explores real laboratory scenarios, highlighting how U0126’s selectivity and reproducibility address common experimental challenges. Practical guidance is provided for workflow optimization and vendor selection, supporting informed use in cancer biology and cellular signaling research.

• Ivermectin in Translational Parasitology: Bridging Mechanism

  2026-06-15

  This article delivers a thought-leadership perspective on Ivermectin as a broad-spectrum anti-parasitic, connecting mechanistic insight with actionable strategies for translational researchers. By mapping evidence from both parasitology and advanced tumor biology, we set a new standard for experimental rigor and strategic planning in anti-parasitic research.

• Phosbind Acrylamide: Precise Phosphate-Binding for SDS-PAGE

  2026-06-15

  Phosbind Acrylamide is a specialized phosphate-binding reagent enabling direct, antibody-free detection of protein phosphorylation states during SDS-PAGE. It is optimal for proteins in the 30–130 kDa range and works under physiological pH, streamlining phosphorylation analyses for signaling research.

• CD44-Mediated Metabolic Rewiring in IDH-Mutant AML: New Vuln

  2026-06-14

  This study reveals that CD44 upregulation is indispensable for sustaining oncometabolite production in IDH-mutant acute myeloid leukemia (AML) by rewiring cellular metabolism to support NADPH generation. The findings highlight CD44 as a critical, targetable dependency, suggesting that co-targeting CD44 alongside mutant IDH1 may overcome therapeutic resistance and improve treatment strategies.

• HPF for Highly Reactive Oxygen Species Detection in Cancer R

  2026-06-13

  HPF (Hydroxyphenyl Fluorescein) brings unprecedented specificity to the detection of highly reactive oxygen species in live-cell and tissue assays. By enabling rapid, interference-resistant visualization of oxidative stress, HPF streamlines advanced protocols in cancer therapy research and beyond.

• PD98059 (SKU A1663): Reliable MEK Inhibition for Cancer Rese

  2026-06-12

  This authoritative guide examines real laboratory challenges in cell viability, proliferation, and cytotoxicity assays, demonstrating how PD98059 (SKU A1663) from APExBIO delivers reliable, reproducible solutions for MEK pathway inhibition. Scenario-driven Q&As provide data-backed best practices, protocol optimization, and vendor selection guidance for biomedical researchers and lab technicians.

• High-Throughput BBB Permeability: LLC-PK1-MOCK/MDR1 Model Ad

  2026-06-12

  This study presents a robust high-throughput in vitro blood-brain barrier (BBB) model using LLC-PK1-MOCK/MDR1 cells, enabling accurate prediction of CNS drug permeability. By integrating lysosomal trapping correction, the model improves early-stage compound screening and offers a significant advance for neuropharmacology and translational research.

• CD44-Driven Metabolic Rewiring in IDH-Mutant Leukemia

  2026-06-11

  This study reveals that CD44 is indispensable for sustaining the metabolic adaptation of IDH-mutant leukemia, enabling high-level 2-hydroxyglutarate (2-HG) production via enhanced NADPH generation. The findings highlight a targetable vulnerability in acute myeloid leukemia, positioning CD44-mediated pathways as promising adjuncts to mutant IDH1 inhibition.

16777 records 1/1119 page Next 12345 下5页 Last page